MedTrace Logo

Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma

NCT01617746 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2012-06-12

No results posted yet for this study

Summary

The purpose of this study will be to determine if blockade of endothelin 1 signalling via endothelin receptor A using ambrisentan or dual blockade (A\&B) via bosentan can provide protection against methacholine induced bronchoconstriction in asthma.

Conditions

Interventions

DRUG

Ambrisentan

5mg od two weeks

DRUG

Bosentan

62.5mg bd two weeks

DRUG

Placebo

bd for two weeks

Sponsors & Collaborators

  • NHS Greater Glasgow and Clyde

    collaborator OTHER

  • University of Glasgow

    lead OTHER

Principal Investigators

  • Mark Spears, MBChB PhD · University of Glasgow

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-05-31
Completion
2015-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01617746 on ClinicalTrials.gov